

# In peptic ulcer therapy the search ends here

## INPUT DATA

- Effective ulcer healing
- Prolonged ulcer free period
- Rapid symptomatic relief
- Non-systemic mode of action
- Minimal incidence of side-effects and drug interactions



sucralfate

## Prescribing Information

**Presentation:** Antepsin Tablets 1 gram are white, oblong, biconvex, uncoated tablets scored and engraved 1239 on one side and Ayerst on the other. Each tablet contains 1 gram sucralfate, a basic aluminium salt of sucrose octasulphate. **Uses:** For the treatment of duodenal ulcer, gastric ulcer and chronic gastritis. **Dosage and Administration:** For oral administration. Adults - Usual dose 1 gram 4 times a day to be taken one hour before meals and at bedtime. Maximum daily dose 8 grams. Four to six weeks treatment is usually needed for ulcer healing but up to twelve weeks may be necessary in resistant cases. Antacids may be used as required for relief of pain, but should not be taken half an hour before or after Antepsin. Elderly - There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used. Children - Safety and effectiveness in children have not been established. **Contra-Indications, Precautions, Warnings, etc.** **Contra-indications:** There are no known contra-indications. **Precautions:** 1. The product should only

be used with caution in patients with renal dysfunction. 2. Although animal reproductive studies show no evidence of foetal malformations, safety in pregnant women has not been established and Antepsin should be used during pregnancy only if clearly needed. 3. It is not known whether this drug is excreted in human milk. Caution should be exercised when Antepsin is administered to a nursing woman. **Drug Interactions:** Concomitant administration of Antepsin may reduce the bio-availability of certain drugs as has been observed in animal studies with tetracycline, phenytoin and cimetidine, and in human studies with digoxin. Administration of Antepsin with any of these drugs should be separated by two hours. Since Antepsin may hinder warfarin absorption, caution should be exercised when these two drugs are used together. **Side Effects:** A low incidence of mild side effects, e.g. constipation, has been reported. **Overdosage:** There is no experience in humans with overdosage. Acute oral toxicity studies in animals, however, using doses up to 12g/kg body weight, could not find a lethal dose. Risks associated with

overdosage should, therefore, be minimal. **Pharmaceutical Precautions:** No special requirements for storage are necessary. **Legal Category:** POM. **Package Quantities:** Antepsin 1 gram - Securitainers of 100. **Product Licence Numbers:** PL No. 0607/0045, PA No. 149/4/2. **Basic N.H.S. Price:** Average daily cost 50p.

\*ANTEPSIN is a registered trade mark  
Further information is available on request to the Company  
Date of preparation January 1985



Ayerst Laboratories Ltd.  
South Way, Andover, Hampshire SP10 5LT  
Telephone: Andover (0264) 58711

Distributors in Ireland: Ayerst Laboratories Ltd.  
765 South Circular Road, Islandbridge, Dublin 8

Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT . . .

- rely on acid reduction alone
- rely on pepsin reduction alone
- rely on mucosal protection alone
- profoundly affect intragastric pH

Gastrozepin DOES . . .

- relieve daytime pain
- relieve night-time pain
- reduce antacid intake
- heal peptic ulcers with one 50 mg tablet b.d.


# For the treatment of peptic ulcer

Twice daily


**GASTRO SELECTIVE**  
**Gastrozepin**<sup>®</sup>  
pirenzepine



The gastro-selective  
anti-secretory

**Prescribing Information:** Presentation: White tablets each containing 50 mg of pirenzepine dihydrochloride scored on one face with "G" on one side of the score, and "50" on the other. The obverse is impressed with the symbol . **Uses:** Gastrozepin is indicated in the treatment of gastric and duodenal ulcers. **Dosage:** 50 mg at bedtime, and in the morning before meals. In severe cases the total daily dose may be increased to 150 mg, in divided doses. Continuous therapy may be recommended for up to three months. **Contra-indications, Warnings etc:** Interaction with sympathomimetics and monoamine oxidase inhibitors and Gastrozepin is a theoretical possibility. Gastrozepin is not recommended during pregnancy, although in animal

experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. **Side effects:** occasionally transitory dry mouth and accommodation difficulty may occur. Treatment of overdose: entirely symptomatic. There is no specific antidote. **Basic NHS price:** 50 mg tablets, 60 £20.50. **Product Licence No.:** 50 mg tablets, PLO014-0260.

 Further information is available on request  
The Boots Company PLC, Nottingham

Gastrozepin\* Trade Mark

# THE NEW POWER IN ULCER HEALING



A single 800 mg tablet  
taken at bedtime for four weeks

**TAGAMET**  
**CIMETIDINE 800**


In duodenal ulcer

**Prescribing Information. Presentations** 'Tagamet' Tablets, each containing 800 mg cimetidine (PL 0002/0128: 28 tablets, £16.61) or 400 mg cimetidine (PL 0002/0092: 56 tablets, £16.61). 'Tagamet' Syrup, containing 200 mg cimetidine per 5 ml (PL 0002/0073: 500 ml, £20.43). **Indication** Duodenal ulcer. **Dosage Usual dosage:** Adults. *Duodenal ulcer*, 800 mg once a day at bedtime, or 400 mg b.d. with breakfast and at bedtime. To prevent relapse, 400 mg at bedtime or 400 mg morning and at bedtime. *N.B. For full dosage instructions see Data Sheet.* **Cautions** Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants, phenytoin and theophylline (see Data Sheet). Prolonged treatment: observe patients periodically. Potential delay in diagnosis of gastric cancer (see Data Sheet). Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation. **Adverse reactions** Diarrhoea, dizziness, rash, tiredness. Rarely, mild gynaecomastia, reversible liver damage, confusional states (usually in the elderly or very ill), interstitial nephritis, acute pancreatitis, thrombocytopenia. **Legal category** POM. 27.9.84

Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY. © 1984 Smith Kline & French Laboratories Limited 'Tagamet' is a trade mark

**SK&F**

# Enteric coated granules for improved enzyme delivery in pancreatic insufficiency



**creon**<sup>®</sup>  
pancreatin

---

Capsule dissolves in stomach

---

Granules unaffected by stomach acid

---

Enzymes released in duodenum

---

Mimics the normal digestive process

## A new release for patients with pancreatic insufficiency

**PRESCRIBING INFORMATION: Presentation:** Brown/yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules should be swallowed whole, without chewing, with a little fluid, during the meal. **Contra-indications, Warnings, etc. Contra-indications:** Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. **Warnings:** Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number** 5727/0001.

**duphar**

Further information is available from:

Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

Now, for fast relief of reflux symptoms  
in oesophagitis

THE LIQUID  
WITH THE  
HEALING  
TOUCH

**NEW**  
**PYROGASTRONE**

aluminium hydroxide, carbenoxolone with sodium alginate and potassium bicarbonate

**LIQUID**

**500ml**

**soothing, protecting, healing**

**PYROGASTRONE LIQUID** For the treatment of oesophageal inflammation, erosions and ulcers due to hiatus hernia or other conditions causing reflux and for the relief of heartburn, flatulence and other symptoms associated with reflux oesophagitis. Each 10 ml contains Dried Aluminium Hydroxide BP 300 mg and Carbenoxolone Sodium BP 20 mg in a vehicle with sodium alginate and potassium bicarbonate.

**Adult Dosage:** 10 ml three times a day, immediately after meals, and 20 ml at bedtime. Supplied in bottles containing sufficient powder to prepare 500 ml of liquid. Basic NHS cost of one day's treatment £1.00 (50 ml).

**Contra-indications** Patients suffering from severe cardiac, renal or hepatic failure.

**Precautions** Pyrogastrone should not be given to patients on digitalis therapy unless serum electrolyte levels are monitored weekly and measures taken to prevent the development of hypokalaemia. Special care should be exercised with patients predisposed to sodium and water retention, potassium loss and hypertension (e.g. the elderly and those with cardiac, renal or hepatic disease) since the carbenoxolone content of Pyrogastrone can induce similar changes. Regular monitoring of weight and blood pressure which should indicate the development of such effects is advisable for all patients. A thiazide diuretic should be administered if oedema or hypertension occurs (spironolactone or amiloride should not be used because they

hinder the therapeutic action of carbenoxolone). Potassium loss should be corrected by the administration of oral supplements. No teratogenic effects have been reported with carbenoxolone but careful consideration should be given before prescribing Pyrogastrone for women who may become pregnant.

Pyrogastrone is a registered trade mark. Made under licence from Biorex Laboratories Ltd., England. Brit. Pat. No. 1390683. Further information available from Winthrop Laboratories, Onslow Street, Guildford, Surrey, GU1 4YS.

**WINTHROP**

# A BETTER CHOICE EVERY TIME

**IT WORKS** In the treatment of ulcerative colitis, Colifoam is as effective as steroid enemas. At the same time it has been shown that patients find the foam easier to retain.<sup>1, 2</sup>

**PATIENTS PREFER IT** Colifoam is far more comfortable, more convenient and more acceptable than enemas. Patients also find it easier to administer and that it causes less interference in their daily lives.

**IT COSTS LESS** Surprisingly, despite the fact that it's just as effective and far more comfortable, Colifoam is less expensive. In fact, it can cost up to 1/3 less per dose than a standard proprietary enema.<sup>3</sup>

## IT'S SAFER

Recent clinical data shows Colifoam has extremely low levels of systemic absorption,<sup>4</sup> lower than proprietary prednisolone enemas.<sup>5</sup> Therefore, there is less potential for adrenal suppression which means that Colifoam may be considered safer in long-term use.

# COLIFOAM

hydrocortisone acetate foam

## IN DISTAL INFLAMMATORY BOWEL DISEASE. A BETTER CHOICE EVERY TIME.

**Presentation** White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. **Contra-indications, warnings etc.** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical precautions** Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Shake vigorously before use. Keep out of reach of children. For external use only. **Legal category POM. Package quantities** Aerosol canister containing 25g (approx. 14 applications). **Basic NHS cost** 25g plus applicator, £7.40. **Further Information** One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. **Product Licence No.** 0036/0021. **References** 1. Ruddell WSJ, et al. Gut 1980; 21: 885-889. 2. O'Donoghue D. Modern Medicine, December 1981; 45. 3. Source: Mims. 4. Barr WH, Kline B, Beightol L, Zfass A, Medical College of Virginia/Virginia Commonwealth University, FDA bioavailability submission document October 1981. 5. Lee DAH, et al. Gut 1980; 21: 215-218. Further information is available on request. **Stafford-Miller Ltd.**, Professional Relations Division, Hatfield, Herts. AL10 0NZ.

# INTRODUCING THE ROUTINE EXOCRINE PANCREATIC FUNCTION TEST



Until now, cost and patient discomfort have ruled out the routine investigation of persistent non-specific abdominal symptoms to estimate pancreatic digestive function. The Pancreolauryl Test is a new routine screening test for early exclusion of exocrine pancreatic digestive malfunction as a cause of steatorrhoea, and other abdominal symptoms.

## Simple test procedure

The Pancreolauryl Test is based on the hydrolysis of fluorescein dilaurate by pancreatic esterases liberating fluorescein and lauric acid; fluorescein can then be measured spectrophotometrically. Comparison

of this value with that obtained after ingestion of unesterified fluorescein (i.e. fluorescein sodium) provides an index of exocrine pancreatic function.

## Accuracy confirmed in clinical trials

UK clinical trials have confirmed that the Pancreolauryl Test has sensitivity values ranging from 95-100%, with false negative values less than 0.1%<sup>12</sup>

## Avoids patient intubation

As the Pancreolauryl Test is non-invasive, patient inconvenience is kept to a minimum.

## Inexpensive laboratory procedure

No expensive reagents or special equipment are required for laboratory analysis.

## The Pancreolauryl Test


"...a simple and acceptable screening test for the exclusion of pancreatic exocrine failure as a cause of steatorrhoea".<sup>1</sup>

The Lancet 1982

## Pancreolauryl Test

fluorescein dilaurate and fluorescein sodium  
Accuracy without intubation

**PRESCRIBING INFORMATION.** Pancreolauryl Test **Presentation:** Two blue capsules each containing 174.25 mg (= 0.25 mmol) fluorescein dilaurate. One red capsule containing 188.14 mg (= 0.50 mmol) Fluorescein Sodium B.P. **Indications:** A screening procedure to detect abnormally low exocrine pancreatic function in patients with symptoms associated with disturbances of pancreatic digestive function e.g. recurrent diarrhoea, increased flatulence, fat intolerance and recurrent upper abdominal pain. **Dosage and Administration.** Adults: The patient can eat and drink as usual on the evening prior to the test, but no medicines containing vitamins or digestive aids should be taken. Test Day No. 1: For 10 hours after the start of the test i.e. administration of 2 blue capsules with the standard meal, all urine is collected including a final emptying of the bladder at exactly 10 hours after the start of the test. Test Day No. 2: The control red capsule can be taken the following day ensuring that the same procedure is followed. **Contraindications.** Acute necrotizing pancreatitis. Pregnancy. Not recommended for children. **Interactions with other drugs.** False negative results may arise if digestive aids or vitamins are taken concomitantly. Sulphasalazine can interfere with photometric measurements. **Pack Quantities:** 1-Test Pack (3 capsules) **Product Licence No.:** PL 232/0039. **Basic NHS Cost (excl. VAT) £15.00.** **Special reporting to the CSM required.** Further information available on request from International Laboratories Ltd., (Hospital Division), Charwell House, Wilson Road, Alton, Hants, Date of Preparation 19.2.85. **References:** 1. The Lancet 1982; **ii**: 742-744. 2. J. Clin. Path. 1982; **35** (11): 1240-1243.



For full information on the Pancreolauryl Test, please complete and return this coupon to: International Laboratories Ltd., (Hospital Division), Charwell House, Wilson Road, Alton, Hants GU34 2TJ.

Name \_\_\_\_\_

Title \_\_\_\_\_

Address \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

(Block capitals please)

# Created by Nature. Proven by Science.

*For relief of irritable bowel and abdominal pain*



The unique enteric-coated Colpermin capsule is a long-acting, slow-release product containing a thixotropic paste of peppermint oil. The enteric coating permits this naturally occurring medication to be delivered direct to the distal small bowel. Recent studies confirm that Colpermin offers direct relief to the patient by effectively relaxing intestinal smooth muscle to relieve colonic pain and gaseous distension.

- Irritable bowel symptoms are highly responsive to placebo, but in a recent double-blind cross-over trial, Colpermin was found to be superior to placebo in alleviating irritable bowel symptoms over a three-week period.<sup>1</sup>


- A delayed-release preparation, Colpermin reaches the colon in an unmetabolised state, allowing it to effectively reduce colonic motility.<sup>2</sup>

- Recent ultrasound studies show a consistent inhibitory effect of topical peppermint oil on colon motility and symptomatic improvement of irritable bowel patients given peppermint oil.<sup>3</sup>

#### References:

1. Rees WDW, Evans BK, Rhodes J: Treating irritable bowel syndrome with peppermint oil. *Br Med J* 2:835-836, 1979.
2. Somerville KW, Richmond CR, Bell GD: Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: A pharmacokinetic study. Proceedings of the British Pharmacological Society, Cambridge, April 1983. *Br J Clin Pharmacol*, to be published.
3. Taylor BA, Duthie HL, Oliveira RB, et al: Ultrasound used to measure the response of colonic motility to essential oils. Proceedings of *The International Motility Symposium* Aix-en-Provence, France, September 1983, to be published.

## COLPERMIN™ (enteric-coated peppermint oil) CAPSULES



#### PRESCRIBING INFORMATION

**Presentation:** Enteric-coated gelatin capsule. Each contains 0.2 ml standardised peppermint oil B.P., Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should *not* be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years.



**Contraindications, Warnings, etc. Precautions:** The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424 0009. **Basic NHS Cost:** £10.58 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds. **European Patent No. 0015334.**

UK Patent No. 2006011.

Henlow Trading Estate, Henlow, Beds. SG16 6DS



# Not 'All gas and flatus'

In Irritable Bowel Syndrome

**colofac**<sup>®</sup>   
mebeverine

## Blessed relief

**Colofac is also indicated for the relief of gut spasm secondary to diverticular disease.**

**PRESCRIBING INFORMATION. PRESENTATION:** White, sugar-coated tablets each containing 135 mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. **INDICATIONS:** 1. Irritable Bowel Syndrome. 2. Gastro-intestinal spasm secondary to organic diseases. **DOSAGE AND ADMINISTRATION:** Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. **CONTRA-INDICATIONS, WARNINGS, ETC:** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **PRODUCT LICENCE NO:** 512/0044.

**duphar**


Further information is available upon request to the company.  
Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

# SALAZOPYRIN<sup>®</sup> EN

sulphasalazine

# HAS TOLERABILITY ALL WRAPPED UP

"Patients in whom sulfasalazine induces dyspeptic symptoms alone can be given EN Salazopyrin (entero-soluble) instead, and no more than 5% of these patients will be so troubled by dyspepsia that the treatment has to be discontinued."  
Nielsen, O.H., Scand. J. Gastroenterol., 1982, 17, 389



Get them into the  
**SALAZOPYRIN** habit  
**DAY AFTER DAY AFTER YEAR**  
500mg q.i.d. in ulcerative colitis

#### PRESCRIBING INFORMATION

**Dosage and Administration** Plain or EN Tabs: In acute/moderate attacks 2-4 tablets 4 times a day. In severe attacks give steroids also. Gradually reduce dose after 2-3 weeks to 3-4 tabs/day given indifferently. Suppositories: Two morning and night reducing dose after 3 weeks with improvement. Enema: One to be given at bedtime. Preparation contains adult dose. Children: Reduce adult dose on basis of bodyweight.

**Contra-Indications** Sensitivity to salicylates and sulphonamides. Infants under 2 years. Enema: Sensitivity to parabens.

**Adverse Reactions** Side effects common to salicylates or sulphonamides may occur. Most commonly these are nausea, loss of appetite and raised temperature which may be relieved on reduction of dose: use of EN tablets, enema or suppositories. If serious reactions occur the drug should be discontinued. Rare Adverse Reactions: Haematological: haemolytic anaemia, agranulocytosis, aplastic anaemia. Hypersensitivity: eg rash, fever. Gastrointestinal: eg stomatitis, impaired folate uptake. C, N, S: eg peripheral neuropathy. Fertility: eg reversible oligospermia. Renal: eg proteinuria, crystalluria. Also: Stevens-Johnson syndrome and lung complications: eg fibrosing alveolitis.

**Precautions** Care in porphyria, allergic, renal or hepatic disease. Glucose 6-PD deficiency. Blood checks initially and periodically.

**Pregnancy and Lactation** While the ingestion of drugs in these situations may be undesirable, the severe exacerbations of the disease which can occur commends the continuance of therapy. Long clinical usage and experimental studies have failed to reveal teratogenic or clerical hazards. The amounts of drug present in the milk should not present a risk to a healthy infant.


**Packages and Prices** Plain Tablets (0.5g) 100 & 500. £6.70 for 100. EN Tablets (0.5g) 100 & 500. £8.70 for 100. Suppositories (0.5g) 10 & 50. £2.80 for 10. Enemas (3.0g) 7, £12.10 for 7.

**Product Licence Numbers** Plain Tablets 0009/5006. EN Tablets 0009/5007. Suppositories 0009/5008. Enema 0009/5009.



**Pharmacia**

Further information is available on request  
Pharmacia Limited, Pharmacia House  
Midsummer Boulevard, Milton Keynes MK9 3HP  
Telephone Milton Keynes (0908) 66101



# MEDILOG 1000

## NEW AMBULATORY pH *without tears\**



**\*NO NASAL CATHETER**

- **LOW COST**, system can be justified on less than two procedures a month.
- **RADIO PILL** eliminates need for an irritating nasal catheter (plus it can be used with a catheter for special patients and infants).
- **RELIABLE** Solid State Recorder, stores entire 24 hours of data.
- **AUTOMATICALLY** generates a complete report without any technician interface.

The Medilog 1000 makes ambulatory pH monitoring practical in any setting. By utilizing a comfortable radio pill the need for an unpleasant nasal catheter is completely eliminated. And the cost is low, both in purchase price and ongoing cost of operation. Medilog 1000 is totally automatic, no need for a special operator, just plug in the solid state recorder and in a few minutes you have a complete, easily understood report. Plus the features go on and on including low cost interfacing to a standard personal computer for archiving.

Now is the time to consider Ambulatory pH. For a free demonstration, simply call 800-237-8923.



11526 53rd Street  
Clearwater,  
Florida 33620 U.S.A.  
Telephone (813) 577-4500  
800-237-8923

1 Kintler Road, Abingdon  
Oxon OX14 1BZ,  
England  
Telephone (0290) 14433  
Telex 837346

5 rue Amont Therville  
75017 Paris,  
France  
Telephone (1) 572 20 50  
Telex 64263

Wandersminnstrasse 39  
Postfach 4503 D 6200 Wiesbaden  
West Germany  
Telephone (06421) 70 28 51  
Telex 4180152

Van Ganjstraat 13  
3288 GB Rijswijk  
Holland  
Telephone (70) 909198  
Telex 34668

# PROXIMATE<sup>®</sup>

FLEXIBLE LINEAR STAPLER



Easier access  
—by design


**PROXIMATE<sup>®</sup>**  
FLEXIBLE LINEAR STAPLER

**ETHICON**

ETHICON Ltd, PO. Box 408, Bankhead Avenue,  
Edinburgh EH11 4HF, Scotland  
\*Trademark ©ETHICON Ltd 1985.

# Colonoscopes: Take a Good Look at the Alternative.

- Fuji are the largest optical company in the world.
- Fuji's immense research and development resources have resulted in instruments which are second-to-none.
- Fuji Colonoscopes are guaranteed for 18 months, including accidental damage within the first 12 months.
- Fuji Colonoscopes are serviced by Pysers Ltd, – an established UK company with 50 years' experience in sophisticated optical systems.
- Pysers' factory



Fujinon System 2000 offers a complete range of submersible Colonoscopes

trained service engineers always deliver on time – no ifs or buts.

- Pysers staff are efficient, courteous and friendly – we never take our customers for granted.



Fujinon Fibrescopes  
Pysers Ltd., Fircroft Way,  
Edenbridge, Kent TN8 6HA.  
Edenbridge (0732) 864111 (8 lines)

# WOLF

## *Fiberscope-System*

**Waterproof**  
*soakable*



### **WOLF** -Fiberscope-System


- strong and reliable
- a complete range of fiberscopes
- waterproof and soakable for cleaning and disinfection
- insufflation, aspiration and irrigation pump with automatic disinfection programme

Contact

**WOLF**



WOLF UK LTD  
BOX 47 MITCHAM  
SURREY CR4 4TT  
01-640-3054

UK 2



Renaissance

Mediaeval Crusades



Era of Richard III

# Bodily defence still relies on shields


## NOW! A natural mucosal shield helps heal peptic ulcers!

CAVED-S\* does what no other ulcer therapy can do: it increases the number of mucus-secreting cells<sup>1</sup> with virtually no side effects.<sup>2</sup> This protects the gastric mucosal barrier against damaging agents<sup>3, 4, 5</sup> and reduces ulcer recurrence.<sup>6</sup>

An 88% healing rate in 12 weeks<sup>7</sup> has been reported. Studies also confirm that CAVED-S offers comparable efficacy to cimetidine in healing gastric ulcers<sup>7</sup> and comparable efficacy to ranitidine in healing duodenal ulcers.<sup>6</sup>

#### REFERENCES:

1. Van Marle J, Aarsen PN, Lind A, et al: Deglycyrrhizinated liquorice (DGL) and the renewal of rat stomach epithelium. *Eur J Pharmacol* 72: 219-225, 1981. 2. Cooke WM, Baron JH: Metabolic studies of deglycyrrhizinated liquorice in two patients with gastric ulcer. *Digestion* 4:264-268, 1971. 3. Rees WDW, Rhodes J, Wright JE, et al: Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. *Scand J Gastroenterol* 14:605-607, 1979. 4. Morgan RJ, Nelson LM, Russell RJ, et al: The effect of deglycyrrhizinated liquorice on the occurrence of aspirin and aspirin plus bile acid-induced gastric lesions, and aspirin absorption in rats, abstracted.



# CAVED-S®

(deglycyrrhizinated liquorice, alum hydrox gel, mag carb, sod bic)

## "The Mucosal Shield" for peptic ulcers



Henlow Trading Estate, Henlow, Bedfordshire. SG16 6DS.  
Telephone 0462 813933 Telex: 82313 Tillab C.

#### PRESCRIBING INFORMATION

##### Presentation:

Brown tablets embossed

'CAVED-S', each containing:

Deglycyrrhizinated Liquorice 380 mg  
Dried Aluminum hydroxide gel 100 mg  
Magnesium carbonate 200 mg  
Sodium bicarbonate 100 mg

##### Indications:

For the treatment of peptic ulcer and other allied conditions.

##### Dosage and Administration:

**Adult dose for gastric ulcer:**

2 tablets 3 times a day between meals.

**Adult dose for duodenal ulcer:**

Increase to 2 tablets 6 times a day between meals when necessary.

##### Prophylactic dose:

**Gastric ulcer:**

1 tablet 3 times a day, between meals.

**Duodenal ulcer:**

2 tablets 3 times a day, between meals.

Children's dosage 10-14 years:

half adult dose.

The tablets should be lightly chewed and swallowed with a drink of water, but in exceptional cases of objection to taste, the tablets should be broken into a few pieces and then swallowed with a drink of water. No additional antacids are necessary.

##### Contra-indications, warnings, etc:

Rare cases of mild diarrhoea can occur. No other side-effects have been reported.

Caved-S should be used with caution

in pregnancy.

Basic NHS Price:

60's—£2.83

240's—£10.12

600's—£22.76

PL04245000.



*Gastroenterology* 82:1134, 1982. 5. Morris TJ, Calcraft BJ, Rhodes J, et al: Effect of a deglycyrrhizinated liquorice compound in the gastric mucosal barrier of the dog. *Digestion* 11:355-363, 1974. 6. McAdam WAP, Morgan AC, Pacsoo C, et al: A comparison between ranitidine and Caved-S in duodenal ulcer treatment, abstracted. Proceedings, World Congress of Gastroenterology, Stockholm, June 1982. 7. Morgan AC, McAdam WAP, Pacsoo C: Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. *Gut* 23:545-551, 1982.

## New titles from Churchill Livingstone

Three new volumes in the series  
Contemporary Issues in Gastroenterology

### Peptic Ulcer Disease (Volume 3)

Edited by *Frank P. Brooks*

244 pages 79 illus hardback £49.00

Experts from the USA, the UK, Sweden, Australia, Japan, West Germany and Canada discuss recent developments in the epidemiology, diagnosis, clinical course and treatment of acute, chronic and recurrent peptic ulcers.

#### Topics covered include:

- use of computer-based methods to identify and define peptic ulcers
- role of endoscopy in differential diagnosis, in therapy and in monitoring ulcer healing
- role of aggressive factors (hydrochloric acid and pepsin)
- the importance of a cellular metabolism in determining resistance to injury

### Gallstones (Volume 4)

Edited by *Sidney Cohen and Roger D. Soloway*

358 pages 62 illus hardback £55.00

#### Some important features

- summarizes current knowledge of natural history and expectant management of gallstones
- thoroughly reviews the importance of diet in stone formulation and dissolution
- evaluates present radiologic means of diagnosis
- describes surgical approaches to cholelithiasis and choledocholithiasis
- analyzes the formation of pigment gallstones

### Hormone-Producing Tumors of the Gastrointestinal Tract

(Volume 5)

Edited by *Sidney Cohen and Roger D. Soloway*

172 pages 28 illus hardback £36.00

Details the latest advances in the study of this subject. Acknowledged experts focus on major issues in the understanding, diagnosis and treatment of patients and give their own views on important topics.

#### Areas covered include:

- Regulatory peptides of the gastrointestinal tract and their derivative tumours
- Somatostatinoma
- Pancreatic polypeptide and mixed peptide-producing tumours of the gastrointestinal tract

A major new test

### Gastrointestinal Surgery

Edited by *David Fromm*

1,006 pages (in two volumes) 432 illus (36 in full colour) hardback £135.00

An in-depth reference which combines, in a single source, both technical aspects of an operation and specific pre- and post-operative considerations.

#### 17 experts from the USA and the UK:

- present their procedure of choice and give solid,

well-documented reasons for that choice

- explain important details and concepts of each procedure
- discuss alternative approaches

#### Coverage of each surgical condition includes:

- etiology ■ diagnosis and pre-operative considerations
- operative approaches ■ post-operative considerations
- results ■ complications and their treatment

### Pathology of the Esophagus, Stomach and Duodenum

Edited by *Henry D. Appelman*

310 pages 259 illus hardback £46.00

Leading authorities consider in detail the surgical pathology of a range of common upper gastrointestinal diseases as well as several less common disorders which are currently the focus of controversy and interest.

Topics dealt with include:

Inflammatory and neoplastic diseases of the esophagus . . . Localized and extensive expansions of the gastric mucosa: mucosal polyps and giant folds . . . Endocrine pathology of the upper gastrointestinal . . . Lymphoid proliferation of the stomach

### Gastrointestinal Radiology

Performing and Interpreting the Fluoroscopic Examination

Edited by *David Gelfand*

358 pages 579 illus hardback £56.00

Compact, profusely illustrated new reference covering both the performance and interpretation of gastrointestinal radiologic examinations.

#### Two information-packed sections:

*Part 1: Performing the Gastrointestinal Examination* deals with characteristics of barium sulfate suspensions . . . the latest fluoroscopic and radiographic apparatus . . . innate capabilities and limitations of barium studies . . . newest techniques for examining the esophagus, stomach and duodenum . . . upper gastrointestinal and small bowel examinations . . . standard full column and double-contrast barium enemas . . . patient preparation.

*Part 2: Interpreting the Gastrointestinal Examination* fully covers the normal anatomy and its variants, radiologic manifestations of gross pathologic changes . . . abnormalities of the esophagus and esophago-gastric junction, stomach, duodenum, mesenteric small bowel and colon.

A book to stimulate debate . . .

### Controversies in Gastroenterology

Edited by *Gary Gitnick*

292 pages 10 illus hardback £25.00

23 leading authorities in the field present opposing arguments on topics including:

- corticosteroids in the treatment of alcoholic hepatitis and of chronic active hepatitis B
- endoscopic sphincterotomy in the management of stones in the distal common bile duct
- peritoneal lavage in the treatment of hemorrhagic pancreatitis
- early surgical intervention in the management of gallstone pancreatitis
- the value of perioperative nutritional support

Each chapter contains a brief summary and an evaluation by the editor of the strengths and weaknesses of the arguments presented in that chapter.

Churchill Livingstone



52GA/GUT